To recover your password please fill in your email address
Please fill in below form to create an account with us
SSGXXII: Three or five years of adjuvant imatinib for the treatment of patients with operable GIST with a high risk of relapse: A randomized phase III study.
See ANZCTR for full trial details >
|
Trial Summary: |
The aim of SSGXXII is to compare the effect of giving imatinib for 5 years against 3 years, in patients who have undergone surgery for GIST, with the intent to prevent the tumour from coming back. The trial will look at the effect of the efficacy and safety of 5 years of treatment compared to 3 years. |
|
Supported By: |
Medical Research Future Fund - International Clinical Trials Collaboration Grant, Australian Government Department of Health |
|
Eligibility: |
Patients on standard imatinib treatment with high risk of GIST recurrence following complete surgical resection of GIST. |
|
Registration ID: |
|
|
Participation: |
Australia |
|
Australian Lead Group: |
AGITG |
|
Status: |
Recruiting |
|
Activation Date: |
17 Feb 2022 |
|
Chairs: |
Professor John Zalcberg and A/Prof Sumitra Ananda |
|
Contact: |